ELI-002
Elicio Therapeutics
['pancreatic', 'rectal', 'colorectal', 'elicio,(-delicious)', 'elicio']
$eltx - elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal cancer at the asco annual meeting 
Follow for the latest #healthcare #stockmarket tweets. Visit https://t.co/wA5OfUn0Ee to try our powerful investing tools.